Treatment of Psoriasis Vulgaris with??the Two-Compound Product Calcipotriol/Betamethasone Dipropionate followed by Different Formulations of Calcipotriol

Cassano, Nicoletta; Miracapillo, A; Coviello, C.; Loconsole, Francesco; Bellino, Marco; Veña, Gino Antonio

doi:10.2165/00044011-200626040-00008

Cited by 21 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Since our previous review, 14 a substantial number of new head-to-head trials comparing different pharmacological treatments for psoriasis against each other have been published. This is a very positive development highlighting that the Adalimumab 0Á065 (À0Á038 to 0Á168) Etanercept 2 9 50 mg 0Á235 (0Á140-0Á330) 0Á17 (0Á10-0Á24) 60 Etanercept 1 9 50 mg or 2 9 25 mg 0Á367 (0Á270-0Á464) CSA low dose (2Á5-3 mg) 0Á429 (0Á256-0Á602) Alefacept 0Á547 (0Á442-0Á652) MTX 0Á278 (À0Á211 to 0Á767) Ustekinumab 45 mg Adalimumab 0Á020 (À0Á048 to 0Á089) Etanercept 2 9 50 mg 0Á190 (0Á134-0Á246) 0Á11 (0Á03-0Á19) 60 Etanercept 1 9 50 mg or 2 9 25 mg 0Á322 (0Á264-0Á380) CSA low dose (2Á5-3 mg) 0Á384 (0Á229-0Á539) Alefacept 0Á502 (0Á430-0Á574) MTX 0Á233 (À0Á249 to 0Á716) Adalimumab Etanercept 2 9 50 mg 0Á170 (0Á100-0Á240) Etanercept 1 9 50 mg or 2 9 25 mg 0Á302 (0Á230-0Á374) CSA low dose (2Á5-3 mg) 0Á364 (0Á204-0Á524) Alefacept 0Á482 (0Á399-0Á565) MTX 0Á213 (À0Á271 to 0Á697) 0Á44 (0Á32-0Á56) 35 Etanercept high dose 2 9 50 mg Etanercept 1 9 50 mg or 2 9 25 mg 0Á132 (0Á072-0Á192) 0Á17 (0Á12-0Á22) 10,43,48,49 CSA low dose (2Á5-3 mg) 0Á194 (0Á038-0Á349) Alefacept 0Á312 (0Á239-0Á385) MTX 0Á043 (À0Á440 to 0Á526) Etanercept low dose 1 9 50 mg or 2 9 25 mg CSA low dose (2Á5-3 mg) 0Á062 (À0Á094 to 0Á218) Alefacept 0Á180 (0Á105 to 0Á255) MTX 0Á089 (À0Á394 to 0Á572) CSA high dose (5 mg) CSA low dose (2Á5-3 mg) 0Á35 (0Á20 to 0Á51) 20,24 CSA low dose (2Á5-3 mg) Alefacept 0Á118 (À0Á044 to 0Á280) MTX 0Á151 (À0Á353 to 0Á655) 0Á15 (À0Á01 to 0Á30) 23,25 Alefacept MTX 0Á269 (À0Á216 to 0Á754) MTX Fumaric acid 0Á05 (À0Á18 to 0Á27) 30 RD, risk difference, interpreted as the excess chance for PASI 75 response of intervention vs. comparator; CI, confidence interval; CSA, ciclosporin A; MTX, methotrexate. a Based on all placebo-controlled trials on the interventions included (see Fig.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

“…Such clinical data may form an important foundation to support the evidence‐based care of psoriasis patients with itch symptoms. The following discussion reviews the itch effect of topical agents, systemics and biologics, and phototherapy, as revealed in recent studies (Table ) . Itch relief remains a significant gap in the treatment landscape for psoriasis, as not all patients are able to achieve control of this symptom, even with cleared or markedly improved skin.…”

Section: Management Of Itch In Psoriasismentioning

confidence: 99%

Itch: an under‐recognized problem in psoriasis

Elewski

Alexis

Lebwohl

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis has historically been considered a nonpruritic dermatosis, in contrast with atopic dermatitis. Thus, itch has often been underappreciated and overlooked in psoriasis. However, increasing evidence over the past decade has shown that itch can be one of the most prevalent and burdensome symptoms associated with psoriasis, affecting almost every patient to some degree. Itch can involve the entire body, although it predominantly affects the legs, hands, back, body and especially the scalp. Uncontrolled itch can significantly impact all aspects of the well‐being and quality of life of the patient. While there has been some progress in trying to better understand the pathophysiology of itch in psoriasis, more research effort and interest are needed. This under‐recognition of itch in psoriasis is clearly reflected in the dearth of treatment options targeting itch despite significant advancement in treating the lesions themselves. Recently, however, clinical studies have begun to include itch as a study outcome. The resulting data have demonstrated concomitant antipruritic benefits and improved Psoriasis Area and Severity Index (PASI) scores with mainstay treatments for psoriasis, such as topical corticosteroids and vitamin D analogs, phototherapies, and various systemics and biologics. This article takes a closer look at this debilitating symptom, reviewing the available epidemiology data for psoriatic itch, presenting the current understanding of psoriatic itch pathophysiology and highlighting important clinical data for various treatment options for itch. Practical considerations for increasing the recognition of itch as well as improving its management in psoriasis are also provided.

show abstract

“…Yet a study on combination therapy with and calcitriol are roughly equally effective, it may be assumed that calcitriol therapy is more effective than tacalcitol 133,136,166,168,[173][174][175][176],. Use with salicylate-based keratolytics or dithranol preparations can diminish the effectiveness of the drug.…”

mentioning

confidence: 99%